Your browser doesn't support javascript.
loading
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Zimmer, Alexandra S; Nichols, Erin; Cimino-Mathews, Ashley; Peer, Cody; Cao, Liang; Lee, Min-Jung; Kohn, Elise C; Annunziata, Christina M; Lipkowitz, Stanley; Trepel, Jane B; Sharma, Rajni; Mikkilineni, Lekha; Gatti-Mays, Margaret; Figg, William D; Houston, Nicole D; Lee, Jung-Min.
Afiliação
  • Zimmer AS; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. alexandra.zimmer@nih.gov.
  • Nichols E; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Cimino-Mathews A; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, MD, USA.
  • Peer C; Johns Hopkins Hospital Department of Pathology, Baltimore, MD, USA.
  • Cao L; Johns Hopkins Hospital Department of Oncology, Baltimore, MD, USA.
  • Lee MJ; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
  • Kohn EC; Genetics Branch, National Cancer Institute, Bethesda, MD, USA.
  • Annunziata CM; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Lipkowitz S; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Trepel JB; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Sharma R; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Mikkilineni L; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Gatti-Mays M; Johns Hopkins Hospital Department of Oncology, Baltimore, MD, USA.
  • Figg WD; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Houston ND; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Lee JM; Johns Hopkins Hospital Department of Pathology, Baltimore, MD, USA.
J Immunother Cancer ; 7(1): 197, 2019 07 25.
Article em En | MEDLINE | ID: mdl-31345267
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Saude_da_mulher / Mama / Tipos_de_cancer / Mama / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ftalazinas / Piperazinas / Quinazolinas / Neoplasias do Endométrio / Neoplasias de Mama Triplo Negativas / Anticorpos Monoclonais / Recidiva Local de Neoplasia Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Saude_da_mulher / Mama / Tipos_de_cancer / Mama / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ftalazinas / Piperazinas / Quinazolinas / Neoplasias do Endométrio / Neoplasias de Mama Triplo Negativas / Anticorpos Monoclonais / Recidiva Local de Neoplasia Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos